Glyburide in Treating Malignant Cerebral Edema. Blocking Sulfonyl Urea One (SUR1) Receptors

Abstract

Cerebral edema is a serious side effect of malignant stroke. On average 70,000 patients are diagnosed with
malignant cerebral edema every year, of those patients, approximately 60-80% results in fatalities. The
treatment of cerebral edema includes multimodality approaches.
In this article, we discuss our experience with glibenclamide in the treatment for malignant cerebral edema.
Our study indicates that glibenclamide may decrease cerebral edema by blocking SUR1 receptors in ischemic stroke and non-ischemic etiologies.